This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatologic Procedures  • Dermatologic Procedures, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Rosemarie H. Liu, MD; Joerg Albrecht, MD; Victoria P. Werth, MD

Arch Dermatol. 2006;142:37-41.

Objective  To examine whether patients had received bisphosphonates at the beginning of planned long-term glucocorticoid therapy, which is recommended by the guidelines from the American College of Rheumatology to prevent glucocorticoid-induced osteoporosis, prior to referral to a tertiary dermatology clinic.

Design  Cross-sectional study.

Setting  Tertiary referral center.

Patients  We reviewed 35 patients from an established cohort of patients referred with chronic skin diseases that require prolonged glucocorticoid use.

Main Outcome Measure  The use of osteoporosis prophylaxis was determined by medical chart review and communication with patients.

Results  Of 35 patients, 28 (80%) were not receiving any bisphosphonates at referral. These patients began glucocorticoid therapy 17 months (median, 6 months; range, 1-102 months) prior to referral. The proportion of patients treated with bisphosphonates in our cohort did not change after the guidelines of the American College of Rheumatology were published.

Conclusions  For patients of non–child-bearing potential with dermatological diseases in which prolonged oral corticosteroid treatment is anticipated, bisphosphonates should be prescribed concomitantly with the initiation of glucocorticoid therapy.

Author Affiliations: Eastern Virginia Medical School, Norfolk (Dr Liu); Department of Dermatology, University of Pennsylvania, Philadelphia (Drs Albrecht and Werth); and Veterans Administration Hospital, Philadelphia (Dr Werth).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update
Brett T. Summey and Gil Yosipovitch
Arch Dermatol. 2006;142(1):82-90.
ABSTRACT | FULL TEXT  

The Era of Cooperation
Michael P. Heffernan
Arch Dermatol. 2006;142(1):93-95.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial
STOCH et al.
The Journal of Rheumatology 2009;36:1705-1714.
ABSTRACT | FULL TEXT  

Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy
Heffernan et al.
JAMA 2006;295:1300-1303.
FULL TEXT  

The Era of Cooperation
Heffernan
Arch Dermatol 2006;142:93-95.
FULL TEXT